All In Biotech

Drug Trial Radar · NCT02876900

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 617 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

617

Actual

Start

Aug 2016

Primary completion

Jun 2018

Study completion Jun 2018

Sponsor

Lead sponsor
Noven Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • Low Dose Asenapine maleate transdermal patchDrug

    The study will evaluate low dose Asenapine maleate transdermal patch

  • High Dose Asenapine maleate transdermal patchDrug

    The study will evaluate high dose Asenapine maleate transdermal patch

  • PlaceboDrug

    The study will evaluate placebo transdermal patch.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Syndrome Scale (PANSS) Total Score: Change From Baseline to Week 6.Time frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Noven Pharmaceuticals, Inc.

    Jersey City, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.